FY2024 Earnings Estimate for Vericel Co. Issued By HC Wainwright (NASDAQ:VCEL)

Vericel Co. (NASDAQ:VCEL) – Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Vericel in a research report issued on Friday, August 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.21 for the year, up from their prior estimate of $0.18. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Vericel’s Q2 2025 earnings at $0.04 EPS.

Several other equities research analysts have also weighed in on VCEL. Stephens lifted their price target on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Truist Financial upped their target price on shares of Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. BTIG Research lowered their price target on shares of Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, July 15th. TD Cowen initiated coverage on shares of Vericel in a report on Thursday, June 20th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, StockNews.com lowered shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average price target of $54.50.

Vericel Stock Performance

VCEL stock opened at $46.75 on Monday. Vericel has a fifty-two week low of $30.18 and a fifty-two week high of $54.08. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -4,675.00 and a beta of 1.70. The business’s 50 day moving average price is $47.14 and its two-hundred day moving average price is $47.00.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The business had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VCEL. Nisa Investment Advisors LLC boosted its holdings in Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 220 shares during the last quarter. MCF Advisors LLC grew its holdings in shares of Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares during the period. Swiss National Bank grew its holdings in shares of Vericel by 0.4% in the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock worth $4,656,000 after acquiring an additional 400 shares during the period. Arizona State Retirement System increased its position in Vericel by 3.3% during the second quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock valued at $590,000 after acquiring an additional 406 shares during the last quarter. Finally, CWM LLC lifted its holdings in Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 504 shares during the period.

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total transaction of $772,100.00. Following the sale, the chief executive officer now owns 220,752 shares in the company, valued at $9,739,578.24. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Sean C. Flynn sold 6,772 shares of Vericel stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $45.02, for a total value of $304,875.44. Following the completion of the sale, the insider now directly owns 487 shares in the company, valued at approximately $21,924.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total transaction of $772,100.00. Following the transaction, the chief executive officer now owns 220,752 shares in the company, valued at approximately $9,739,578.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,791 shares of company stock valued at $3,101,269. Insiders own 5.20% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.